MedTrace Logo

Assessment of a New Fluorescence Imaging Technique Using Biopsies From Prostate Resection

NCT03157856 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2019-01-15

No results posted yet for this study

Summary

In this study, we aim to evaluate the feasibility of anti-PSMA labelling to detect post-operative prostatic tissues by two ex vivo fluorescence techniques. We will evaluate the feasibility and detection of anti-PSMA labelling by:

1. / the FEMTO-ST institute medical device,
2. / the confocal microscope that will be used to measure fluorescence spectra of biological samples.

Conditions

  • Cancer Prostate

Interventions

OTHER

Fluorescence assessment

All subjects of the study are going to have a radical prostatectomy. The FEMTO-ST medical device is used on 3 fresh biopsies (2 healthy and 1 malignant) which will be prelevated from the resected prostate in order to determine the prostatic or non-prostatic nature of tissue.

Sponsors & Collaborators

  • TIMC-IMAG

    collaborator OTHER

  • Clinical Investigation Centre for Innovative Technology Network

    collaborator NETWORK

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Jean Luc Descotes, MD, PhD · Grenoble Alpes University Hospital

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-11
Primary Completion
2018-10-07
Completion
2019-01-08

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03157856 on ClinicalTrials.gov